Immunologic characteristic | Mean ± SD | Range |
---|---|---|
Prevalence | ||
HIV History | ||
Length of HIV diagnosis, months | 196 ± 99 | 48–360 |
Previous history of AIDS-defining diagnosis, % | 25 | --- |
Previous history of opportunistic infections, % | 19 | --- |
Undetectable viral load > 3 years, % | 100 | --- |
Compliance with HAART > 3 years, % | 99 | 90–100 |
HAART-induced side effects | ||
Metabolic syndrome, % | 22 | --- |
Lipodystrophy, % | 78 | --- |
Lipoatrophy, % | 63 | --- |
Lipoaccumulation, % | 67 | --- |
HAART Exposure | ||
Cumulative HAART (any agent), months | 157 ± 88 | 36–336 |
Cumulative exposure PI, months | 91 ± 57 | 0–249 |
Cumulative exposure NRTI, months | 163 ± 122 | 40–464 |
Cumulative exposure “high risk” PI, months | 47 ± 33 | 0–103 |
Cumulative exposure NNRTI, monthsa | 22 ± 63 | 0–156 |
Cumulative exposure INSTI, monthsa | 5.5 ± 12.6 | 0–48 |
Cumulative exposure “high risk” NRTI, monthsa | 44.2 ± 73.9 | 0–273 |
Immunologic History | ||
CD4+ cell counta | 594 ± 326 | 242–2597 |
CD8+ cell counta | 686 ± 356 | 312–1944 |
CD4+/CD8+ ratioa | 78 ± 47 | 30–313 |